Dr. Wang earned his PhD at Johns Hopkins University under Dr. Bert Vogelstein and an MHS in Biostatistics under Dr. Rafael Irizarry, one of the world’s most highly cited quantitative scientists, following molecular biology training at Nankai University and an MBA from Wharton. For over 18 years, he has stood at the forefront of clinical proteomics and genomics, translating disruptive discovery into clinical transformation.
He pioneered the first platform to quantify mutant protein copies in single human cells and built scalable mass spectrometry frameworks that propelled proteomics into rigorous clinical biomarker validation. Using ovarian cancer as a proving ground, he demonstrated that mass spectrometry–based proteomics can detect malignancy significantly earlier than genomics-driven approaches. He later developed Valid-NEO® for direct neoantigen detection and created Complete360®, a clinical-grade multi-omics platform enabling ultra-deep biomarker quantification from body fluids.
As Founder of Complete Omics Inc., Dr. Wang integrates scientific depth with entrepreneurial force, redefining precision diagnostics and embedding omics intelligence into everyday healthcare.
We are building transformative multi-omics technologies today that redefine how diseases are detected, monitored, and understood—converting ultra-deep molecular resolution into clinically actionable intelligence that enables earlier detection, sharper stratification, and truly mechanism-driven intervention.
By integrating clinical-grade proteomics, metabolomics, genomics, and advanced computational analytics into scalable, standardized platforms, we are engineering a future where precision healthcare is proactive, personalized, and seamlessly embedded into everyday human life.
Biography
Pioneering leaders in clinical proteomics, translating deep scientific innovation into robust, clinically deployable assays.
Contact Form